1. BMPR2 mutations and endothelial dysfunction in pulmonary arterial hypertension (2017 Grover Conference Series)
   Andrea Frump et al, 2018, Pulmonary Circulation CrossRef
2. 2-Methoxyestradiol in Pulmonary Arterial Hypertension: A New Disease Modifier
   Stevan P. Tofovic et al, 2019, Interventional Pulmonology and Pulmonary Hypertension - Updates on Specific Topics [Working Title] CrossRef
3. Kinases as potential targets for treatment of pulmonary hypertension and right ventricular dysfunction
   Astrid Weiss et al, 2021, British Journal of Pharmacology CrossRef
4. Therapeutic effect of dichloroacetate against atherosclerosis via hepatic FGF21 induction mediated by acute AMPK activation
   Byong-Keol Min et al, 2019, Experimental & Molecular Medicine CrossRef
5. Steps forward in the treatment of pulmonary arterial hypertension: latest developments and clinical opportunities
   Jessica B. Badlam et al, 2017, Therapeutic Advances in Chronic Disease CrossRef
6. Emerging therapeutics in pulmonary hypertension
   Matthew K. Hensley et al, 2018, American Journal of Physiology-Lung Cellular and Molecular Physiology CrossRef
7. Mesenchymal stromal cell-derived exosomes improve mitochondrial health in pulmonary arterial hypertension
   Sarah E. Hogan et al, 2019, American Journal of Physiology-Lung Cellular and Molecular Physiology CrossRef
8. The emerging role of NOTCH3 receptor signalling in human lung diseases
   Manish Bodas et al, 2022, Expert Reviews in Molecular Medicine CrossRef
9. Investigative Therapies in Pulmonary Arterial Hypertension
   Karen A. Fagan, 2015, Diagnosis and Management of Pulmonary Hypertension CrossRef
10. Rats with a Human Mutation of NFU1 Develop Pulmonary Hypertension
    Maki Niihori et al, 2020, American Journal of Respiratory Cell and Molecular Biology CrossRef
11. Mechanisms and treatment of pulmonary arterial hypertension
    Hossein-Ardeschir Ghofrani et al, 2024, Nature Reviews Cardiology CrossRef
12. Pharmacology of Pulmonary Arterial Hypertension: An Overview of Current and Emerging Therapies
    Monika Spaczyńska et al, 2020, ACS Pharmacology & Translational Science CrossRef
13. Mitochondria dysfunction: A novel therapeutic target in pathological lung remodeling or bystander?
    David J. Rowlands, 2016, Pharmacology & Therapeutics CrossRef
14. Estradiol Metabolism: Crossroads in Pulmonary Arterial Hypertension
    Stevan P. Tofovic et al, 2019, International Journal of Molecular Sciences CrossRef
15. Idiopathic pulmonary fibrosis and pulmonary hypertension: Heracles meets the Hydra
    Keshava Rajagopal et al, 2021, British Journal of Pharmacology CrossRef
16. The Search for Disease-Modifying Therapies in Pulmonary Hypertension
    Chen-Shan Chen Woodcock et al, 2019, Journal of Cardiovascular Pharmacology and Therapeutics CrossRef
17. Increased Pyruvate Dehydrogenase Kinase 4 Expression in Lung Pericytes Is Associated with Reduced Endothelial-Pericyte Interactions and Small Vessel Loss in Pulmonary Arterial Hypertension
    Ke Yuan et al, 2016, The American Journal of Pathology CrossRef
18. Novel molecular insights and public omics data in pulmonary hypertension
    Camila Lopez-Crisosto et al, 2021, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease CrossRef